ScreenerHero

GYREGyre Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · gyretx.com
6.910USD-3.36%Mkt Cap: 732.69M $P/E: —

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfe…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap732.69M $
Enterprise Value729.97M $
Revenue (TTM)109.82M $
Gross Profit111.17M $
Net Income (TTM)5.03M $
Revenue/Share1.172 USD
Last Price6.910 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees625
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)117.00
PEG—
EV/EBITDA-60.17
EV/Revenue6.65
P/S6.78
P/B6.90
EPS (TTM)-0.21
EPS (Forward)0.06
52W Range
5.46037% of range9.420
52W High9.420 USD
52W Low5.460 USD
Profitability
Gross Margin95.35%
Oper. Margin-47.62%
EBITDA Margin-11.05%
Profit Margin4.31%
ROE4.74%
ROA3.03%
Growth
Revenue Growth-2.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF1.01M $
CapEx (TTM)1.92M $
FCF Margin1.71%
FCF Yield0.26%
Net Debt-71.38M $
Net Debt/EBITDA5.88
Balance Sheet
Debt/Equity0.01
Current Ratio4.26
Quick Ratio3.59
Book Value/Sh1.018 USD
Cash/Share0.7050 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJan 12, 2023
Splits
Last Split1:15
Split DateOct 31, 2023
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)18.67 USD
Upside (mean)+170.1%
Target Range18.00 USD – 20.00 USD
$18.00+170.1% to mean$20.00
# Analysts3
Ownership
Shares Out.106.03M
Float35.94M
Insiders74.40%
Institutions8.20%
Short Interest
Short Ratio27.9d
Short % Float6.13%
Short % Out.1.72%
Shares Short1.82M
Short (prev mo.)1.83M
Technical
SMA 506.365 (+8.6%)
SMA 2007.203 (-4.1%)
Beta4.82
S&P 52W Chg18.16%
Avg Vol (30d)55.43K
Avg Vol (10d)60.77K
Technical Indicators
RSI (14)60.1
MACD0.1748
MACD Signal0.0873
MACD Hist.+0.0875
BB Upper7.201 USD
BB Middle6.347 USD
BB Lower5.493 USD
BB Width26.90%
ATR (14)0.3203 USD
Vol Ratio (20d)1.21x